Xatmep—the first and only ready-to-use methotrexate oral solution is now available.
Silvergate Pharmaceuticals, Inc., participants in the development and commercialization of safe medicines for children, announced that Xatmep (methotrexate) Oral Solution—the first and only FDA-approved methotrexate oral solution—is now available for ordering. Xatmep is indicated for the treatment of acute lymphoblastic leukemia (ALL) and the management of polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients.
“Xatmep is an exciting product in that it provides an FDA-approved, ready-to-use oral solution of methotrexate for children without the need for needles, crushing of tablets, or compounding into a liquid formulation,” said Frank Segrave, president & CEO, Silvergate Pharmaceuticals, Inc. “As a company, we continue to focus on pediatric medications that are safe, effective, and readily available.”
Xatmep (methotrexate) Oral Solution, 2.5 mg/mL, is a ready-to-use product that requires no preparation, facilitating ease of dispensing at the pharmacy. Xatmep is manufactured under CGMPs in accordance with FDA regulations.
It eliminates the need for needles, crushing or splitting tablets, or compounding tablets into a liquid formulation. It requires refrigeration, but may be stored at room temperature for 60 days after dispensing to the patient. Xatmep will be available through an extensive network of pharmacies.
(Source: PR Newswire)